These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37798034)

  • 1. Safety and feasibility of faecal microbiota transplantation for patients with Parkinson's disease: a protocol for a self-controlled interventional donor-FMT pilot study.
    Vendrik KE; Chernova VO; Kuijper EJ; Terveer EM; van Hilten JJ; Contarino MF;
    BMJ Open; 2023 Oct; 13(10):e071766. PubMed ID: 37798034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial.
    Woodhouse CA; Patel VC; Goldenberg S; Sanchez-Fueyo A; China L; O'Brien A; Flach C; Douiri A; Shawcross D
    BMJ Open; 2019 Feb; 9(2):e023518. PubMed ID: 30772848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study.
    Jitsumura M; Cunningham AL; Hitchings MD; Islam S; Davies AP; Row PE; Riddell AD; Kinross J; Wilkinson TS; Jenkins GJ; Williams JG; Harris DA
    BMJ Open; 2018 Oct; 8(10):e021987. PubMed ID: 30341117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STOP-Colitis pilot trial protocol: a prospective, open-label, randomised pilot study to assess two possible routes of faecal microbiota transplant delivery in patients with ulcerative colitis.
    Quraishi MNN; Yalchin M; Blackwell C; Segal J; Sharma N; Hawkey P; McCune V; Hart AL; Gaya D; Ives NJ; Magill L; Loi S; Hewitt C; Gerasimidis K; Loman NJ; Hansen R; McMullan C; Mathers J; Quince C; Crees N; Iqbal T
    BMJ Open; 2019 Nov; 9(11):e030659. PubMed ID: 31719078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for a double-blind, randomised, placebo-controlled pilot study for assessing the feasibility and efficacy of faecal microbiota transplant in a paediatric Crohn's disease population: PediCRaFT Trial.
    Pai N; Popov J; Hill L; Hartung E
    BMJ Open; 2019 Nov; 9(11):e030120. PubMed ID: 31784432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation.
    Kuai XY; Yao XH; Xu LJ; Zhou YQ; Zhang LP; Liu Y; Pei SF; Zhou CL
    Microb Cell Fact; 2021 May; 20(1):98. PubMed ID: 33985520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal microbiota transplantation (FMT) in Norwegian outpatients with mild to severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): protocol for a 12-month randomised double-blind placebo-controlled trial.
    Skjevling L; Goll R; Hanssen HM; Johnsen PH
    BMJ Open; 2024 Jun; 14(6):e073275. PubMed ID: 38858151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial.
    Bruggeman A; Vandendriessche C; Hamerlinck H; De Looze D; Tate DJ; Vuylsteke M; De Commer L; Devolder L; Raes J; Verhasselt B; Laukens D; Vandenbroucke RE; Santens P
    EClinicalMedicine; 2024 May; 71():102563. PubMed ID: 38686220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
    Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
    BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal microbiota transplant as a potential treatment for Parkinson's disease - A case series.
    Segal A; Zlotnik Y; Moyal-Atias K; Abuhasira R; Ifergane G
    Clin Neurol Neurosurg; 2021 Aug; 207():106791. PubMed ID: 34237681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal microbiota transplantation therapy for Parkinson's disease: A preliminary study.
    Xue LJ; Yang XZ; Tong Q; Shen P; Ma SJ; Wu SN; Zheng JL; Wang HG
    Medicine (Baltimore); 2020 Aug; 99(35):e22035. PubMed ID: 32871960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial.
    Scheperjans F; Levo R; Bosch B; Lääperi M; Pereira PAB; Smolander OP; Aho VTE; Vetkas N; Toivio L; Kainulainen V; Fedorova TD; Lahtinen P; Ortiz R; Kaasinen V; Satokari R; Arkkila P
    JAMA Neurol; 2024 Sep; 81(9):925-938. PubMed ID: 39073834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility, Acceptability, and Safety of Faecal Microbiota Transplantation in the Treatment of Major Depressive Disorder: A Pilot Randomized Controlled Trial.
    Green JE; Berk M; Mohebbi M; Loughman A; McGuinness AJ; Castle D; Chatterton ML; Perez J; Strandwitz P; Athan E; Hair C; Nierenberg AA; Cryan JF; Jacka F
    Can J Psychiatry; 2023 May; 68(5):315-326. PubMed ID: 36637229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol for a randomised, placebo-controlled pilot study for assessing feasibility and efficacy of faecal microbiota transplantation in a paediatric ulcerative colitis population: PediFETCh trial.
    Pai N; Popov J
    BMJ Open; 2017 Aug; 7(8):e016698. PubMed ID: 28827258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of fecal microbiota transplantation in patients with Parkinson's disease: clinical trial results from a randomized, placebo-controlled design.
    Cheng Y; Tan G; Zhu Q; Wang C; Ruan G; Ying S; Qie J; Hu X; Xiao Z; Xu F; Chen L; Chen M; Pei Y; Zhang H; Tian Y; Chen D; Liu X; Huang H; Wei Y
    Gut Microbes; 2023 Dec; 15(2):2284247. PubMed ID: 38057970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised, placebo-controlled, double-blinded trial of fecal microbiota transplantation in severe obesity: a study protocol.
    Hanssen HM; Fjellstad MS; Skjevling L; Johnsen PH; Kulseng B; Goll R; Almå KH; Valle PC
    BMJ Open; 2023 Dec; 13(12):e073242. PubMed ID: 38151280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study).
    Dougé A; Ravinet A; Corriger A; Cabrespine A; Wasiak M; Pereira B; Sokol H; Nguyen S; Bay JO
    BMJ Open; 2023 May; 13(5):e068480. PubMed ID: 37130682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
    Zhao Z; Ning J; Bao XQ; Shang M; Ma J; Li G; Zhang D
    Microbiome; 2021 Nov; 9(1):226. PubMed ID: 34784980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.
    Halkjær SI; Christensen AH; Lo BZS; Browne PD; Günther S; Hansen LH; Petersen AM
    Gut; 2018 Dec; 67(12):2107-2115. PubMed ID: 29980607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study.
    Crothers JW; Chu ND; Nguyen LTT; Phillips M; Collins C; Fortner K; Del Rio-Guerra R; Lavoie B; Callas P; Velez M; Cohn A; Elliott RJ; Wong WF; Vo E; Wilcox R; Smith M; Kassam Z; Budd R; Alm EJ; Mawe GM; Moses PL
    BMC Gastroenterol; 2021 Jul; 21(1):281. PubMed ID: 34238227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.